# BPC-157 TB-500 Dosage in the Research Literature

> BPC-157 TB-500 dosage as it appears in the research literature: rodent per-body-weight figures, no validated blend dose, no human protocol, and a non-monotonic result that undercuts loading.

There is no validated dose for the blend. The numbers below are animal-model figures and human single-agent reference points, reported as research context — not a regimen.

## BPC-157 TB-500 Dosage in the Research Literature

BPC-157 TB-500 dosage has no validated figure at the blend level. No peer-reviewed combination dose-finding study exists, so every number associated with the pairing comes from single-compound animal work or from human studies of one constituent in isolation. Commercial research-product vials commonly pair the two at fixed combined masses — for example ~10 mg BPC-157 plus ~10 mg TB-500, or a 20 mg combined vial — but those label ratios have no controlled-trial basis [9].

The rodent figures, expressed per body weight and never translatable to a human regimen: BPC-157 was studied frequently at ~10 microg/kg and ~10 ng/kg, with gastric-ulcer cytoprotection at 400-800 ng/kg in rats [1]. The TB-500 / Thymosin Beta-4 side spans a wide range — 2-18 mg/kg intraperitoneally in a rat embolic-stroke dose-response study (optimal modeled near 3.75 mg/kg, with 18 mg/kg giving no benefit), and 150 microg twice weekly intraperitoneally for six months in an mdx muscular-dystrophy study [4]. Human single-agent reference points exist only for full-length Thymosin Beta-4 — intravenous Thymosin Beta-4 tolerated to high single doses in a Phase 1 program — not for the heptapeptide and not for the blend [9]. These are doses studied in named species and contexts, not instructions.

## What is the half-life of BPC-157 and TB-500?

Half-life is one of the most-asked dosing questions for the blend, and it is one the literature largely cannot answer.

#### What is the half-life of BPC-157 and TB-500?

No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157 elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study; human intravenous full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide [9].

#### How do you reconstitute a BPC-157 / TB-500 blend?

Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated; a common practice is to reconstitute them separately or in a shared vial. Product identity, purity and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [9]. This describes research handling, not a human-use instruction.

## BPC 157 TB 500 Oral vs Injected

BPC 157 TB 500 oral products are marketed, but the pharmacokinetic case for them is uneven. BPC-157 is studied as a "stable gastric" peptide and has been administered perorally in rodent models, which is the basis of the oral framing [9]. TB-500 is a different molecule with no validated oral pharmacokinetics, and blend oral products lack validated absorption data entirely. The underlying efficacy studies for both peptides most often used injected routes — intraperitoneal in rodents, with subcutaneous and intramuscular predominant in research-community handling of the blend [1][9]. Oral versus injected is therefore not a settled question for the pairing; it is two different molecules with two different absorption pictures and no combination pharmacokinetic study to reconcile them.

#### How often should you inject BPC-157 and TB-500?

There is no validated dose or schedule for the blend. Community "loading then maintenance" protocols and fixed-ratio vials (e.g. 10 mg plus 10 mg) have no basis in controlled human trials [9]. The underlying rodent studies used per-body-weight dosing that does not translate to a human regimen [1]; framing stays research-only.

## How do you cycle BPC-157 and TB-500?

Cycling protocols circulate widely in forums and rest on no controlled evidence, and one preclinical result actively cuts against the "more is better" logic that loading schedules assume.

#### How do you cycle BPC-157 and TB-500?

No validated cycling protocol exists; community "loading then maintenance" schedules have no controlled-trial basis. A rat embolic-stroke study even found Thymosin Beta-4 dosing non-monotonic — 18 mg/kg gave no benefit — undermining "more is better" loading rationales [4]. Any cycle described in forums is not validated dosing.

---

Two peptides held on one status board — BPC-157 and TB-500 graded against their own studies, the combination row left reading NO-HUMAN-DATA and the 503A status posted as it stands, with no clinic behind the board and nothing here prescribed or sold.